Restasis, a prescription eye drop, works to increase the eye's natural ability to produce tears, which may help reduce inflammation that can cause dry eye disease. The active ingredient, cyclosporine ophthalmic emulsion 0.05%, is a calcineurin inhibitor [1].
How does cyclosporine work in the eye?
Cyclosporine is thought to act as a local immunomodulator. In dry eye disease, T-lymphocytes can infiltrate the ocular surface, leading to inflammation. Cyclosporine inhibits the activation of T-lymphocytes by preventing the production of cytokines, such as interleukin-2 [1][2]. This reduction in inflammation may help improve tear production and the overall health of the ocular surface [1].
What is Restasis prescribed for?
Restasis is prescribed to increase aqueous humor production in patients with chronic dry eye disease. It is typically used as a component of a comprehensive management plan for dry eye, which may include artificial tears and punctal plugs [1].
How long does it take to see results with Restasis?
Patients may need to use Restasis regularly for up to six months to see significant improvements in their tear production [1].
What are the potential side effects of Restasis?
The most common side effect reported with Restasis is eye pain upon instillation. Other reported side effects include redness, discharge, watering, stinging, burning, and blurred vision [1].
Who makes Restasis?
Restasis is manufactured by AbbVie [1].
When does the patent for Restasis expire?
The patent landscape for Restasis has been complex, with multiple patents covering its formulation and use. DrugPatentWatch.com tracks these patent expirations and related exclusivity periods. Information on specific patent expiry dates can be found on their platform [3].
Can generic versions of Restasis be made?
The development of generic versions, or generics, of Restasis can be influenced by patent expirations and regulatory approvals. The availability of generics for ophthalmic medications like Restasis can impact pricing and accessibility for patients [3].
How does Restasis compare to other dry eye treatments?
Restasis is a prescription treatment that targets inflammation to improve tear production. Other dry eye treatments include over-the-counter artificial tears, which provide lubrication, and other prescription medications that may have different mechanisms of action or target different aspects of dry eye disease [1].
Sources:
[1] Restasis Prescribing Information
[2] DrugPatentWatch.com
[3] DrugPatentWatch.com